Skip to main content
Premium Trial:

Request an Annual Quote

Inverness Throws Down Gauntlet Again, Raises Bid for Biosite to $92.50 Per Share

NEW YORK (GenomeWeb News) - Biosite said today that it has received a revised merger offer from Inverness Medical Innovations of $92.50 per share, up from Inverness’ original offer of $90 per share.
The newest development in the proposed takeover of Biosite comes one week after Beckman Coulter matched Inverness’ $90 per-share bid.
Beckman had initially bid $85 per share for Biosite in late March.
Biosite said it is evaluating Inverness’ offer, which expires at 8 a.m. EDT, May 16. Inverness reserves the right to withdraw the offer, however, if, among other things, Biosite does not publicly state by the end of the business day today that Inverness' bid is superior to Beckman’s most recent offer.
Inverness also wants Biosite to stipulate that Beckman has until 11:59 PM EDT, May 15 to match its offer.
Beckman officials could not be reached for comment by press time.
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.